[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myelodysplastic-myeloproliferative-neoplasm-not-otherwise-specified":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":16,"states":17},"Myelodysplastic\u002FMyeloproliferative Neoplasm, Not Otherwise Specified",1,0,[8],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07468916","Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia",[12],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:17:25.718160Z","2026-05-05T02:43:26.934773Z",[],[]]